



DEPARTMENT OF DEFENSE (AFHSC)

Avian Influenza A (H7N9): Laboratory Testing Guidance as of 28 FEB 2014



1. Case Definitions

Clinicians should consider the possibility of avian influenza A (H7N9) virus infection in persons presenting with acute febrile respiratory illness and an appropriate recent travel history to places where H7N9 has been diagnosed in people (currently China) or an appropriate exposure history. Current case definitions, last updated 14 JAN 2014, are available at: <http://www.cdc.gov/flu/avianflu/h7n9-case-definitions.htm>

Confirmed Case: A patient with novel influenza A (H7N9) virus infection that is confirmed by the Centers for Disease Control and Prevention's (CDC) Influenza Laboratory or a CDC certified public health laboratory using methods agreed upon by CDC and the Council for State and Territorial Epidemiologists (CSTE). Confirmation of avian influenza A (H7N9) viruses may be made by public health laboratories following CDC-approved protocols for detection of avian influenza A (H7N9) virus, or by laboratories using an FDA-authorized test specific for detection of avian influenza A (H7N9) virus.

Probable Case: A patient with illness compatible with influenza for whom laboratory diagnostic testing is positive for influenza A, negative for H1, negative for H1pdm09, and negative for H3 by RT-PCR, and therefore not able to be subtyped.

Case Under Investigation: A patient with illness compatible with influenza, meeting either of the following exposure criteria, and for whom laboratory confirmation is not known or pending, or for whom test results do not provide a sufficient level of detail to confirm novel influenza A virus infection.

- A patient who has had recent contact (within 10 days of illness onset) with a confirmed or suspected case of infection with avian influenza A (H7N9) virus,

OR

- A patient who has had recent travel (within 10 days of illness onset) to a country where human cases of avian influenza A (H7N9) virus have recently been detected or where novel influenza A (H7N9) viruses are known to be circulating in animals,

OR

- Unprotected exposure to live avian influenza A (H7N9) virus in a laboratory.

2. Antiviral Treatment

While minimal data are available regarding early neuraminidase inhibitor treatment of persons infected with H7N9 virus, laboratory testing with functional assays indicates that most H7N9 viruses are susceptible to neuraminidase inhibitors (oseltamivir and zanamivir), but resistant to adamantanes (amantadine and rimantadine). Therefore, amantadine and rimantadine are not recommended for treatment of H7N9 virus infection.

- Because of the potential severity of illness associated with H7N9 virus infection, **it is recommended that all confirmed cases, probable cases, and H7N9 cases under investigation receive antiviral treatment** with a neuraminidase inhibitor as early as possible. Treatment should be initiated even if it is more than 48 hours after onset of illness.
- Laboratory testing and initiation of antiviral treatment should occur simultaneously; treatment should not be delayed for laboratory confirmation of influenza or H7N9 infection.
- Please see [Antiviral Drugs: Dosage \(ACIP\)](#) for additional guidance on the use of influenza antiviral agents. Oseltamivir is recommended for treatment of persons of any age; zanamivir is recommended for children aged 7 and older.

For more information: <http://www.cdc.gov/flu/avianflu/h7n9-antiviral-treatment.htm>

3. Laboratory Testing

A. Human Diagnostic Testing:

On April 22, 2013, the FDA issued an Emergency Use Authorization (EUA) for the CDC Human Influenza Virus Real-Time Polymerase Chain Reaction (RT-PCR) Diagnostic Panel-Influenza A/H7 (Eurasian Lineage) Assay (**Catalog # FluEUA-01**) for **presumptive detection of novel influenza A (H7N9) in conjunction** with the FDA cleared CDC Human Influenza Virus RT-PCR Diagnostic Panel (**Catalog# FluIVD03**) on the Applied Biosystems (ABI) 7500 Fast Dx RT-PCR Instrument. This assay provides *in vitro* qualitative detection and characterization of human influenza A/H7 (Eurasian Lineage) viruses on upper and lower respiratory tract clinical specimens and is to be used only for patients that present with influenza-like illness (ILI) and meet the clinical and epidemiologic criteria for testing suspect specimens (i.e. patients who meet the Case Under Investigation criteria).

Ordering site: <https://www.influenzareagentresource.org/>

To order a kit (only 1 kit of 1,000 reactions per lab permitted at this time) a laboratory must meet the following criteria:

- **CLIP certification** as a highly complex laboratory (<http://www.tricare.mil/tma/ocmo/cclm.aspx>), and
- **CDC Influenza Division Qualification** for influenza diagnostic testing.

Mr. Dan Harms (Dan.Harms@dha.mil, phone: 803-781-8314/571-215-4237) is the DoD point-of-contact regarding DoD qualified laboratories with the CDC Influenza Branch.

CDCFluorder@cdc.gov will remain open to assist those labs with extenuating circumstances; however, the Influenza Reagent Resource web page is the preferred method for ordering.

Specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and submitted to your nearest military medical treatment facility laboratory for proper handling and testing. Department of Defense laboratories using the CDC Human Influenza Virus RT-PCR Diagnostic Panel-Influenza A/H7 (Eurasian Lineage) Assay are:

Laboratory	Location
Eisenhower Army Medical Center (EAMC)	USA - Fort Gordon GA
Landstuhl Regional Medical Center	Germany
Tripler Army Medical Center	USA - Honolulu HI
Brian Allgood Army Community Hospital	Republic of Korea
Womack Army Medical Center	USA - Fort Bragg NC
William Beaumont Army Medical Center (WBAMC)	USA - Fort Bliss TX
Brooke Army Medical Center (BAMC)	USA - Joint Base San Antonio TX
Carl R. Darnall Medical Center (CRDAMC)	USA - Fort Hood TX
Madigan Army Medical Center (MAMC)	USA - Joint Base Lewis McChord WA
US Air Force School of Aerospace Medicine (USAFSAM)	USA - Wright Patterson AFB OH
Naval Health Research Center (NHRC)	USA - San Diego CA
Naval Medical Research Unit 3 (NAMRU-3)	Egypt

Naval Hospital Yokosuka	Japan
Naval Hospital Guam	Guam
793rd Med Det, Camp Arifjan	Kuwait
Naval Infectious Diseases Diagnostic Laboratory (NIDDL)	USA - Silver Spring MD
Naval Medical Research Unit 6 (NAMRU-6)	Peru
Naval Medical Center Portsmouth	USA - Portsmouth VA

Viral culture should **not** be attempted in these cases unless a **BSL 3+** facility is available to receive and culture specimens.

Please note that by using this EUA kit, there are additional requirements set forth in the EUA such as confirmation of positive result by the CDC, reporting assay performance characteristics to the CDC, and distributing CDC provided Fact Sheets with the results for Providers:

<http://www.fda.gov/downloads/MedicalDevices/Safety/EmergencySituations/UCM349062.pdf>

and Patients:

<http://www.fda.gov/downloads/MedicalDevices/Safety/EmergencySituations/UCM349064.pdf>

Also please note that this assay, as with all assays for human diagnostics, must be verified in each laboratory per CLIA/CLIP regulations. The CDC is working with the appropriate partners to create a panel to use for this required verification of performance prior to diagnostic testing and will distribute the panel to those laboratories that have received the kits.

B. Non-Diagnostic Testing (Surveillance/Research):

Laboratories interested in **non-clinical** testing should register with the CDC Laboratory Support for Influenza Surveillance website at www.cdc.gov/flu/clis to procure resources for novel influenza A (H7N9) testing.

The WHO assay protocol can be found here:

http://www.who.int/influenza/gisrs_laboratory/cnic_realtime_rt_pcr_protocol_a_h7n9.pdf

The sequences have been deposited in the EpiFlu™ Database, found on the GISAID website

<http://platform.gisaid.org/epi3/frontend#457751>

The below laboratories currently have surveillance testing capability:

Armed Forces Research Institute of Medical Sciences (AFRIMS)	Thailand
Naval Medical Research Unit 3 (NAMRU-3)	Egypt
Naval Medical Research Unit 6 (NAMRU-6)	Peru
Naval Medical Research Unit 2 Phnom Penh (NAMRU-2)	Cambodia
Naval Medical Research Unit 2 Singapore (NAMRU-2)	Singapore
Naval Health Research Center (NHRC)	USA - San Diego CA

4. Reporting

- AFHSC recommends that possible cases of novel influenza infection be reported immediately as Reportable Medical Events (RMEs <http://afhsc.mil/reportableEvents>) and through their local public health chain of command. A new Novel Influenza diagnosis screen has been added to DRSi. If you suspect a case of influenza A (H7N9), report it under this diagnosis and answer as many questions as possible.
- Novel influenza strains are a Nationally Notifiable Disease (NDD) and should be reported to the CDC (<http://wwwn.cdc.gov/nndss/default.aspx>), your state health department, and host nation if applicable.

- Human influenza caused by a new subtype must be reported to the WHO under the International Health Regulations.

5. Additional information

Guidance can be found at:

Armed Forces Health Surveillance Center: <http://afhsc.mil>

CDC: <http://www.cdc.gov/flu/avianflu/h7n9-virus.htm>

WHO: http://www.who.int/influenza/human_animal_interface/faq_H7N9/en/

6. AFHSC POC:

For further information, contact the AFHSC's Division of Integrated Biosurveillance (DIB) or the Division of Global Emerging Infections Surveillance & Response Systems (GEIS):

Email: usarmy.ncr.medcom-afhsc.list.dib@mail.mil

Phone:

Dr. Rohit A. Chitale, Director, (DIB): 443-253-0525; desk: 301-319-3241; BB: 240-507-7492

MAJ Karyn Havas, Deputy Director, (DIB): 301-319-3272

Dr. Stic Harris, Team Lead, Alert & Response Operations (DIB): 301-319-3297

CAPT Michael Cooper, Lead, Respiratory Surveillance (GEIS): 301-319-3258